Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.38 |
| ▸ | PIM1 | P11309 | 8/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319209 | 0.88 | ALDH1A1 (0.40) | NPC1PIM2PIM1PIM3KDR | |
| SCHEMBL319312 | 0.86 | KDM4E (0.42) | PIM2PIM1PIM3L3MBTL1KDM4E | |
| SCHEMBL1711977 | 0.76 | PIM1 (0.44) | PIM2PIM1PIM3L3MBTL1KDM4E | |
| SCHEMBL319370 | 0.75 | AR (0.37) | PIM2PIM1PIM3KDM4E | |
| SCHEMBL319384 | 0.73 | IAPP (0.46) | NPC1PIM2PIM1PIM3 | |
| SCHEMBL21503648 | 0.73 | NPC1 (0.61) | NPC1TP53MDM4GAACETP | |
| SCHEMBL318957 | 0.73 | GAA (0.40) | PIM2PIM1PIM3GAA | |
| SCHEMBL1910596 | 0.73 | KDM4E (0.36) | PIM2PIM1PIM3L3MBTL1KDM4E | |
| SCHEMBL12488326 | 0.72 | ECE1 (0.34) | PIM2PIM1PIM3L3MBTL1KDM4E | |
| SCHEMBL29599851 | 0.72 | KDM4E (0.53) | PIM2PIM1PIM3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | NPC1 2570/4885PIM2 4/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.